222 related articles for article (PubMed ID: 32882690)
1. Reduction of Bladder Volume after BCG Immunotherapy.
Yang C; Lv Z; Li Y
Urol Int; 2021; 105(1-2):155-158. PubMed ID: 32882690
[TBL] [Abstract][Full Text] [Related]
2. [Calmette-Guerin bacillus disseminated infection after intravesical instillation].
Borré S; Brustia D; Rosa F; Brondolo R; Rizzo G; Garavelli PL
Recenti Prog Med; 2002 Apr; 93(4):247-8. PubMed ID: 11989131
[TBL] [Abstract][Full Text] [Related]
3. Disseminated Bacillus Calmette-Guérin (BCG) infection with pulmonary and renal involvement: A rare complication of BCG immunotherapy. A case report and narrative review.
Marques M; Vazquez D; Sousa S; Mesquita G; Duarte M; Ferreira R
Pulmonology; 2020; 26(6):346-352. PubMed ID: 31711964
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
[TBL] [Abstract][Full Text] [Related]
5. Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.
Saluja M; Gilling P
Int J Urol; 2018 Jan; 25(1):18-24. PubMed ID: 28741703
[TBL] [Abstract][Full Text] [Related]
6. [Sepsis and multiple organ failure after BCG-instillation for bladder cancer].
Elmer A; Bermes U; Drath L; Büscher E; Viertel A
Internist (Berl); 2004 Aug; 45(8):935-9. PubMed ID: 15138643
[TBL] [Abstract][Full Text] [Related]
7. Ocular involvement following Bacillus Calmette-Guerin immunotherapy for bladder carcinoma.
Cugati S; Gilhotra JS; Lake S; Gordon DL
Clin Exp Ophthalmol; 2014 Jul; 42(5):494-5. PubMed ID: 24372891
[No Abstract] [Full Text] [Related]
8. Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.
Pérez-Jacoiste Asín MA; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Tejido Á; San Juan R; Arrebola-Pajares A; Lizasoain M; Prieto S; Aguado JM
Medicine (Baltimore); 2014 Oct; 93(17):236-254. PubMed ID: 25398060
[TBL] [Abstract][Full Text] [Related]
9. Granulomatous balanoposthitis after intravesical Bacillus-Calmette-Guerin instillation therapy.
Yusuke H; Yoshinori H; Kenichi M; Akio H
Int J Urol; 2006 Oct; 13(10):1361-3. PubMed ID: 17010022
[TBL] [Abstract][Full Text] [Related]
10. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
11. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal tuberculosis caused by intravesical instillation with Bacillus Calmette-Guérin (BCG) following nephroureterectomy in a patient with bladder and upper tract urothelial cancer: a case report.
Allaeys C; De Backer P; Decaestecker K; Berquin C; Decaestecker K; Callens S; Van Praet C
Acta Clin Belg; 2023 Jun; 78(3):257-260. PubMed ID: 35943041
[TBL] [Abstract][Full Text] [Related]
13. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
[TBL] [Abstract][Full Text] [Related]
14. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
Gandhi NM; Morales A; Lamm DL
BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
[TBL] [Abstract][Full Text] [Related]
15. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer.
Tozawa K; Okamura T; Sasaki S; Kawai N; Ito Y; Hayashi Y; Kohri K
Urol Int; 2001; 67(4):289-92. PubMed ID: 11741130
[TBL] [Abstract][Full Text] [Related]
16. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
17. Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy.
Ozbakkaloglu B; Tünger O; Sürücüoglu S; Lekili M; Kandiloglu AR
Int Urol Nephrol; 1999; 31(1):49-53. PubMed ID: 10408303
[TBL] [Abstract][Full Text] [Related]
18. [Systemic BCG reactions after intravesical BCG therapy. A report of four cases].
Sfaxi M; Langar H; Ouni A; Riahi Y; El Aidli S; Daghfous R; Ben Abdeladhim A; Chébil M
Therapie; 2008; 63(1):43-7. PubMed ID: 18387275
[TBL] [Abstract][Full Text] [Related]
19. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
20. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
Turker P; Turkeri L
Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
